Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Simpson

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Immunotherapy|February 27, 2025
ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitisEmma Guttman-Yassky, Eric Simpson, Robert Bissonnette, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 11, 2025
Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitisMelinda Gooderham, Mahreen Ameen, H Chih-Ho Hong, et al.
Journal of the American Association of Nurse Practitioners|September 14, 2018
Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trialsSusan J Tofte, Kim Papp, Neil Sadick, et al.
Journal of the American Academy of Dermatology|July 21, 2022
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trialAndrew Blauvelt, Richard G Langley, Jean-Philippe Lacour, et al.
The British Journal of Dermatology|March 30, 2023
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trialsAndrew Blauvelt, Jacob P Thyssen, Emma Guttman-Yassky, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 9, 2023
The vIGA-AD scale for atopic dermatitis: Uptake in the past 5 years and position of the International Eczema CouncilRobert Bissonnette, Eric Simpson, Lawrence F Eichenfield, et al.
Journal of the American Academy of Dermatology|August 15, 2016
Strategies used for measuring long-term control in atopic dermatitis trials: A systematic reviewSebastien Barbarot, Natasha K Rogers, Katrina Abuabara, et al.
The New England Journal of Medicine|July 10, 2014
Dupilumab treatment in adults with moderate-to-severe atopic dermatitisLisa A Beck, Diamant Thaçi, Jennifer D Hamilton, et al.
The Journal of Dermatological Treatment|June 11, 2026
Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summaryEric Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
Dermatology and Therapy|January 19, 2026
Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt StudyJonathan I Silverberg, Lindsay Ackerman, Jerry Bagel, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Immunotherapy|February 27, 2025
ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitisEmma Guttman-Yassky, Eric Simpson, Robert Bissonnette, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 11, 2025
Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitisMelinda Gooderham, Mahreen Ameen, H Chih-Ho Hong, et al.
Journal of the American Association of Nurse Practitioners|September 14, 2018
Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trialsSusan J Tofte, Kim Papp, Neil Sadick, et al.
Journal of the American Academy of Dermatology|July 21, 2022
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trialAndrew Blauvelt, Richard G Langley, Jean-Philippe Lacour, et al.
The British Journal of Dermatology|March 30, 2023
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trialsAndrew Blauvelt, Jacob P Thyssen, Emma Guttman-Yassky, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 9, 2023
The vIGA-AD scale for atopic dermatitis: Uptake in the past 5 years and position of the International Eczema CouncilRobert Bissonnette, Eric Simpson, Lawrence F Eichenfield, et al.
Journal of the American Academy of Dermatology|August 15, 2016
Strategies used for measuring long-term control in atopic dermatitis trials: A systematic reviewSebastien Barbarot, Natasha K Rogers, Katrina Abuabara, et al.
The New England Journal of Medicine|July 10, 2014
Dupilumab treatment in adults with moderate-to-severe atopic dermatitisLisa A Beck, Diamant Thaçi, Jennifer D Hamilton, et al.
The Journal of Dermatological Treatment|June 11, 2026
Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summaryEric Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
Dermatology and Therapy|January 19, 2026
Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt StudyJonathan I Silverberg, Lindsay Ackerman, Jerry Bagel, et al.
Pageof 8